RNA Clinical Trials Videos
-
Capstan Therapeutics' CEO Laura Shawver On In Vivo Cell Engineering
11/10/2022
Capstan Therapeutics' CEO, Laura Shawver, Ph.D., talks us through the company's in vivo CAR therapies and what led to the in vivo cell engineering breakthrough that has been decades in the making. Shawver explains the promise of harnessing mRNA and targeted LNP delivery to train a patient’s body to make CAR-T cells in vivo. She also details best practices to garner funding and investment partnership.
-
Achieving mRNA-LNP Delivery Beyond The Liver
11/28/2022
In this segment, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, discuss which ongoing industry efforts to improve LNPs and the RNA/mRNA cargo they're watching closely that could help the RNA industry move beyond hepatic delivery.
-
RNA-Based Therapeutics With Nutcracker Therapeutics' Dr. Geoff Nosrati
11/21/2022
Nutcracker Therapeutics is a preclinical biopharma company developing multimodal RNA-based therapeutics for HPV-driven tumors, T-cell lymphoma, and Genitourinary tumors. On this episode of the Business of Biotech, Chief Business Officer Geoff Nosrati, Ph.D. offers a comprehensive view of the RNA-based therapeutics landscape and sheds light on what he perceives as an advantageous position at Nutcracker — the capacity to manufacture RNA in-house. If you're curious about the expanding science behind RNA-based therapeutics and their application in biotech, this conversation with a scientist-turned-chief business officer (Nosrati earned his Ph.D. in Biochemistry and Molecular Biology) is a can't-miss episode.
-
Approving The World’s First saRNA Vaccine: Arcturus’ Regulatory Experience
5/10/2024
Explore the behind-the-scenes best practices of the company implemented that led to the approval of the world’s first saRNA vaccine in Japan.
-
Precision ADVANCE: Unravelling The Complexity Of CGTx Development
10/12/2021
Need help unravelling the complexity of CGTx development? Four experts explain Precision ADVANCE’s unique approach. Spend 50 seconds with Anshul Mangal, Deb Phippard, Megan Liles, and Philip Cyr.
-
How A Sponsored CMC Platform Accelerates mRNA Projects Into The Clinic
1/31/2023
Developing a client-sponsored Target Product Profile (TPP) and Analytical Target Profile (ATP) is critical to move your drug product to clinic efficiently and meet acceptance criteria.
-
PepGen's SVP Head Of Clinical Development On Delivery Of Oligonucleotide Therapies
10/27/2022
PepGen, a Cambridge, MA-based biotech, is advancing oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. SVP Head of Clinical Development Dr. Michelle Mellion explains PepGen's trial of PGN-EDO51, the company’s lead product candidate for the treatment of DMD patients whose mutations are amenable to an exon 51 skipping approach. She also explains how the delivery of oligonucleotide therapies differ from other techniques in genetic medicine, and much more.
-
Mitigating Financial Risk Before Selecting An Outsourcing Vendor
9/25/2023
Gain insight from several clinical operations experts into the significance of meticulous contract examination when choosing an outsourcing partner.
-
Michelangelo Meets mRNA | ARW on RNA Ep04
5/4/2023
Hosted by Cell & Gene Collaborative's Director Anna Rose Welch, ARW on RNA puts a creative spin on the emerging mRNA + RNA therapeutics industry. Here, in Episode 4, Welch explores the parallels that exist between the oft-overlooked history of Michelangelo's David and the mRNA therapeutics sector's own R&D history, as well as where the mRNA space hopes to move in the future.
-
Oligonucleotide Opportunities in DMD with PepGen's James McArthur, Ph.D.
7/25/2022
Among the more prevalent genetic conditions, Duchenne muscular dystrophy affects an estimated one in 3,500 male births worldwide. It's caused by mutations of the DMD gene, which regulates the production of a protein called dystrophin. Approved DMD treatments haven't demonstrated strong clinical outcomes, but James McArthur, Ph.D. and his team at PepGen are seeking to change that with a pipeline of disease-modifying peptide-conjugated oligonucleotide candidates derived from the company's Enhanced Delivery Oligonucleotide platform. The Business of Biotech caught up with Dr. McArthur at PepGen's Cambridge headquarters to learn more.